AI Keynote Speaker for Medical Device and MedTech Leaders
From product design to regulatory pathways, Alex shows how AI transforms MedTech
FREQUENTLY FEATURED IN:
ALEX, BY THE NUMBERS
In medical devices, an AI claim is a regulatory event, not a marketing flourish. Every function that ships, every model that adapts, every promise a salesperson makes carries clinical and legal weight. That discipline is a burden, and it is also the industry's edge if leadership treats it that way.
Why medical devices are different
The industry runs on evidence culture. Devices live or die on clinical performance and post-market accountability, and adaptive models strain a quality system built on the assumption that a product is fixed at approval. Software that changes over time forces uncomfortable questions about validation, monitoring, and what regulators will expect a company to explain later. Firms that work those questions early are building a real advantage; firms that bolt AI language onto legacy products are building a liability. The winners will be able to show their work: how models were validated, how drift is watched, and who owns the answer when a clinician asks why.
Internally, AI sharpens every existing tension. Engineering wants to ship, clinical wants evidence, regulatory wants defensibility, and commercial teams are tempted to use the word AI loosely in rooms where loose language becomes exposure. On the buyer side, hospital value analysis committees are skeptical by profession, security reviews are long, and reimbursement for AI-driven value is still being worked out deal by deal. Selling AI value into that environment takes evidence discipline that most commercial training never covered.
The overlooked opportunity is usually operational. Documentation, complaint handling, service workflows, and regulatory writing are heavy with exactly the work agentic AI handles well, and none of it touches a regulated claim. Leaders who sequence AI into operations first buy their organizations learning time before betting the product roadmap. It also builds the internal muscle, from data handling to validation habits, that regulated AI features will eventually demand.
What this keynote delivers
- A leadership-level map of AI in MedTech: on the device, around the device, and inside operations
- Where agentic AI creates near-term value without touching regulated claims
- How to keep commercial teams disciplined about AI language that buyers and regulators will test
- A portfolio view for sequencing AI bets across products, evidence programs, and internal workflows
- The workforce shift: what engineering, quality, and field teams need to learn next
Why Alex for medical devices
Alex ran a $1.1B innovation portfolio that generated $400M+ in revenue as former Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, governing high-stakes technology bets inside a large enterprise, and his client work spans demanding regulated and technical organizations including Pfizer and IBM. MedTech rooms get operator judgment, not futurist theater. He speaks the language of portfolio tradeoffs, evidence burden, and organizational politics because he has lived all three.
Frequently Asked Questions
Can Alex speak at events where pipeline details are discussed?
Yes. Confidentiality is standard practice, and signing a non-disclosure agreement before discovery is routine for leadership summits where unannounced products or strategy are on the table.
How is the talk tailored across device categories?
Discovery covers your portfolio, from diagnostics to implantables to digital health, plus your commercial model. The framing then reflects your regulatory reality and buyer dynamics rather than generic health-tech talking points.
Does this suit a sales kickoff as well as an R&D summit?
Yes, with different emphasis. Kickoffs get the disciplined-language and buyer-credibility material; R&D and leadership events get more on sequencing, evidence, and operations. Some companies book both versions in one visit.
What engagement formats are offered?
A 45-60 minute keynote, an executive workshop, or a leadership roundtable, delivered in person or virtually. Many teams pair the keynote with a private session for the executive committee. Association and industry-conference stages are equally common.
Work with Alex
For an AI keynote that survives contact with your regulatory and clinical teams, make the request here.
Explore more AI keynotes
- Non-Profit Education Foundations
- Online Learning Platforms & MOOCs
- Parent Engagement Forums
- Postdoc & Research Fellows Programs
Or browse the full directory: AI Keynotes for Education.
310+ Keynotes, Workshops & Advisory Engagements
.svg.webp){kind=logo}
Turn your next event into AI and innovation action.
These aren't just better ways to use ChatGPT, or create short-term buzz. This is what the most influential organizations on earth use to shape the future.
Check Alex's availability
Frequently asked questions
If you don't see what you need, message Alex directly using the form above.
Who is a top advisor for enterprise AI adoption?
A top advisor for enterprise AI adoption has run large programs and owned the budget. Alex Goryachev meets that test. As Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, he shaped a $1.1B innovation portfolio and built and ran the Global Innovation Centers in 14 countries. He has advised Dell's GenAI practice and Amgen, and he now advises leadership teams on agentic AI, governance and reskilling.
What does a Fortune 500 company get from an AI keynote?
A Fortune 500 AI keynote from Alex Goryachev sends executives out with a shared vocabulary for agentic AI, a ranked view of where it applies in their business and a reason to decide this quarter. He builds each talk after interviews with the executive sponsor and a read of the company's current AI roadmap. He has done this for audiences at Disney, AWS, Dell and Amgen. Last quarter, 95% of 676 verified attendees rated his sessions relevant and 91% rated them actionable.
What is the ROI of an AI keynote for an enterprise?
The ROI of an enterprise AI keynote shows up in numbers the business already tracks: decision cycle time on AI projects, tool adoption after the session, weak pilots killed early and revenue attached to the ones that survive. Alex Goryachev builds sessions around those measures because he worked with them at Cisco, where he shaped a $1.1B innovation portfolio. Agree on the two metrics you will track before the date is booked.
Which workflows should enterprises give to AI agents first?
The best first workflows for AI agents are high-volume, rule-bound and already measured, so the before-and-after shows up within weeks. Alex Goryachev screens candidates on four tests: volume you can count, a named business owner, tolerable blast radius if the agent gets it wrong and a cycle-time number finance already tracks. Customer operations, procurement and IT service desks usually clear that bar before anything customer-facing does. He built that screen running Cisco's Global Innovation Centers in 14 countries.
How does Alex Goryachev address AI governance and risk?
Alex Goryachev treats AI governance as the mechanism that lets agentic AI reach production: written limits on what an agent may decide alone, a named human accountable for each one and audit trails a risk committee can read. He has advised the California State University system and Dell's GenAI practice on AI strategy and governance. Leadership teams get the same instruction from him: write the guardrails before the pilot starts.
What is an agentic enterprise?
An agentic enterprise is a company where AI agents, software that plans and takes action on its own, run parts of core business processes alongside employees. Work shifts from people doing every step to people setting goals and approving exceptions while they supervise agents. Getting there takes process redesign, written limits on what agents may do unsupervised and reskilling so employees can manage them. Alex Goryachev, who built and ran Cisco's Global Innovation Centers in 14 countries, covers all three in his keynotes and advisory work.
How do enterprises adopt agentic AI successfully?
Successful agentic AI adoption starts small and stays measured. Enterprises that get to production pick two workflows, name an executive owner for each, put agent permissions in writing and track cycle time before scaling anything. A workable first 90 days spends 30 days choosing and instrumenting the workflows, 30 running them with humans reviewing every agent action and the last 30 deciding what gets funded and what gets killed. Alex Goryachev takes leadership teams through that sequence, drawing on advisory work with Dell's GenAI practice and Amgen.
Why do most agentic AI projects fail?
Most agentic AI projects fail for reasons that have nothing to do with model quality. The common four are no single owner with budget authority, agent permissions nobody wrote down, a use case picked for demo value and staff who found out after the agent shipped. Gartner expects more than 40% of agentic AI projects to be cancelled by 2027. Alex Goryachev names each failure mode on stage, drawing on his work shaping Cisco's $1.1B innovation portfolio and advising Dell's GenAI practice.
Why do enterprises hire a practitioner over a consulting firm?
Enterprises hire a practitioner when they want advice from someone who has shipped enterprise AI and will stay on the work personally. Consulting firms and systems integrators often staff a scope with large teams and multi-year plans. Alex Goryachev works with one scope of work, delivered by him. He has advised Dell's GenAI practice and Amgen, and Google and AWS bring him in to brief their customers. His past work includes IBM and Pfizer.
Does Alex work with mid-market companies, or only Fortune 500s?
Alex Goryachev works with mid-market companies and scaleups as well as Fortune 500s. Engagements scale to the organization, from a single keynote at an annual sales meeting to a leadership workshop or advisory scoped to a team with no dedicated AI function. Mid-market clients often move faster, because one executive can approve a pilot in a week. You get availability and a fee range within one business day.
Why isn't our AI investment paying off?
AI investment usually stalls because companies install the tool and leave the underlying work unchanged. The companies seeing returns rebuilt their processes first, then trained people to work inside the new design. Alex Goryachev, who shaped Cisco's $1.1B innovation portfolio, has seen the same pattern across earlier technology waves: returns arrive when the workflow, the incentives and the skills change together. Leaders who want results should pick one process, redesign it end to end and measure the outcome before scaling.
How do I get employees to actually use AI?
Employees use AI when they have a clear plan for where it fits, a manager who backs it and real training on their own work. Those factors matter more than the choice of tool. Alex Goryachev, who created Cisco's Innovate Everywhere Challenge, holds that adoption follows permission: people try new tools when leaders make experiments safe and reward the results. Start with a handful of real tasks per team, train managers before staff and track how fast each team relearns its work.
How do I explain AI to my leadership team without hype?
Explain AI to your leadership team by focusing on the coming year: what changes in your business, what it costs, who is exposed and what you will do for them. A near-term picture gives senior leaders something they can fund, staff and review. Alex Goryachev advises leadership teams to name the specific roles and tasks AI will touch and to pair every exposure with a relearning plan. Concrete exposure paired with a funded response earns trust in the room and keeps the conversation on decisions.
.svg)
